|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Among brain tumors, the BRAF (V600E) mutation is frequently associated with pleomorphic xanthoastrocytomas (PXAs) and gangliogliomas (GGs).
|
26264609 |
2015 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing.
|
25346165 |
2015 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
An activating mutation of BRAF (BRAF-V600E) has been reported in a subset of malignant brain tumors.
|
24721513 |
2014 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Future clinical trials should address whether BRAF V600E mutant brain tumour patients will benefit from BRAF V600E-directed targeted therapies.
|
24353007 |
2014 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
PKM2-regulated MLC2 phosphorylation, which is greatly enhanced by EGF stimulation or EGFRvIII, K-Ras G12V and B-Raf V600E mutant expression, plays a pivotal role in cytokinesis, cell proliferation and brain tumour development.
|
25412762 |
2014 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The BRAF V600E mutation and KIAA1549-BRAF fusion are alterations found in several brain tumors and show a distinct prognostic impact in some entities.
|
31181803 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Efficacy of BRAF V600E targeted therapies in brain tumors harboring the mutation has been shown in several case reports and is currently being studied in larger clinical trials.
|
29380516 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This report presents 2 cases of malignant brain tumors with <i>BRAF</i> V600E mutations that were resistant to radiation and temozolomide, and reports on their response to targeted treatment with the BRAF and MEK inhibitors dabrafenib and trametinib.
|
29632053 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Epithelioid glioblastoma is a recognized glioblastoma variant, recently added to the World Health Organization brain tumor classification, with similar prognosis as the classic variant and B-Raf V600E mutations in 50% of the cases.
|
31258848 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The BRAF V600E mutation occurs frequently in certain brain tumors such as pleomorphic xanthoastrocytoma, ganglioglioma, and pilocytic astrocytoma, and less frequently in epithelioid and giant cell glioblastoma.
|
25885250 |
2015 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF V600E-mutations have been described in a modest 6% to 7% of primary central nervous system (CNS) tumors, but with increased prevalence in the pediatric population and in certain brain tumor subtypes.
|
24725538 |
2014 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The patient's resected brain tumor is BRAF V600E mutated, NRAS wild type (WT), and TERT C250T mutated.
|
26597176 |
2015 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Future clinical trials should address whether BRAF (V600E) mutant brain tumor patients will benefit from BRAF (V600E)-directed targeted therapies.
|
21274720 |
2011 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Therefore the BRAF V600E mutation is a highly interesting oncological target in brain tumors.
|
27350555 |
2016 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Pleomorphic xanthoastrocytoma is a rare brain tumor with unique high frequency of BRAF V600E mutation which is plausible for targeted therapy.
|
29200156 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors.
|
25484091 |
2014 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Emerging evidence support the effectiveness of targeted therapies for brain tumors with BRAF V600E mutation.
|
31345255 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.
|
24823863 |
2014 |
|
rs121913500
|
|
|
0.790 |
GeneticVariation |
BEFREE |
The IDH1-R132H mutation predicts a better clinical outcome for glioma patients, and the expression of IDH1-R132H correlates with a favorable outcome in patients with brain tumors.
|
27655638 |
2016 |
|
rs121913500
|
|
|
0.790 |
GeneticVariation |
BEFREE |
The aim of this study is to investigate in depth the prevalence of non-R132H IDH ("non-canonical") mutations in brain tumors classified according to the 2016 WHO scheme and their clonal distribution in neoplastic cells.
|
28748342 |
2017 |
|
rs121913500
|
|
|
0.790 |
GeneticVariation |
BEFREE |
This study evaluates the presence of R132H mutation in isocitrate dehydrogenase (<i>IDH1</i>) gene and the vascular endothelial growth factor (<i>VEGF</i>) +936 C/T polymorphism in brain tumors.
|
28948065 |
2017 |
|
rs121913500
|
|
|
0.790 |
GeneticVariation |
BEFREE |
A total of 343 brain tumors were studied for IDH1 and IDH2 mutations by direct sequencing and for protein expression by immunohistochemistry with mIDH1(R132H) antibody.
|
21643842 |
2011 |
|
rs121913500
|
|
|
0.790 |
GeneticVariation |
BEFREE |
Mean CBF1 expression is significantly increased in isocitrate dehydrogenase 1 (IDH1) R132H mutant glioblastoma and serves as prognostic marker for prolonged overall survival in brain tumours, particularly after therapy with temozolomide.
|
28571041 |
2017 |
|
rs121913500
|
|
|
0.790 |
GeneticVariation |
BEFREE |
Patients/Methods In a prospective cohort study, intratumoral IDH1 R132H mutation and podoplanin were determined in brain tumor specimens (mainly glioma) by immunohistochemistry.
|
29676036 |
2018 |
|
rs121913500
|
|
|
0.790 |
GeneticVariation |
BEFREE |
Here, we describe the isolation of a glioma brain tumor stem cell line (BT142) with an endogenous R132H mutation in IDH1, aggressive tumor-initiating capacity, and 2-HG production.
|
22166263 |
2012 |